TSLA
Tesla
-- 421.060 PLTR
Palantir
-- 80.550 NVDA
NVIDIA
-- 134.700 OXY
Occidental Petroleum
-- 47.130 AMD
Advanced Micro Devices
-- 119.210 
NEWS
Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology
Following a successful first year, Israel Innovation Authority (IIA) approved financing second year of collaboration
HAZEVA and REHOVOT, Israel, Oct. 8, 2024/PRNewswire/ -- Watershed AC ("Watershed", formerly Colors Farm Ltd.), a cutting-edge company in sustainable aquaculture and biotech and Evogene Ltd. ("Evogene") (NASDAQ: EVGN)(TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, together with Ben-Gurion University (BGU), a renowned Israeli academic research institution, announced receiving an approval from IIA for a second year grant to continue developing CRISPR technology for crustaceans, following a successful first year.
The collaboration aims to provide a sustainable solution to existing limitations in gene editing for non-model organisms with sparse genomic data and protocols, focusing on improving key traits such as growth rate, disease resistance, and environmental adaptation in crustaceans, targeting giant freshwater prawn, white leg shrimp and red swamp crayfish.
The global shrimp market size was USD 40.35 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.09% during the 2024-2032 period[1]. The global crayfish market is projected to grow at a CAGR of 31.5% between 2024 and 2032[2]. These growing markets increasingly emphasize the need to expand sustainable aquaculture, making the technology developed in the frame of the collaboration exceptionally relevant.
HAZEVA and REHOVOT, Israel, Oct. 8, 2024/PRNewswire/ -- Watershed AC ("Watershed", formerly Colors Farm Ltd.), a cutting-edge company in sustainable aquaculture and biotech and Evogene Ltd. ("Evogene") (NASDAQ: EVGN)(TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, together with Ben-Gurion University (BGU), a renowned Israeli academic research institution, announced receiving an approval from IIA for a second year grant to continue developing CRISPR technology for crustaceans, following a successful first year.
The collaboration aims to provide a sustainable solution to existing limitations in gene editing for non-model organisms with sparse genomic data and protocols, focusing on improving key traits such as growth rate, disease resistance, and environmental adaptation in crustaceans, targeting giant freshwater prawn, white leg shrimp and red swamp crayfish.
The global shrimp market size was USD 40.35 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.09% during the 2024-2032 period[1]. The global crayfish market is projected to grow at a CAGR of 31.5% between 2024 and 2032[2]. These growing markets increasingly emphasize the need to expand sustainable aquaculture, making the technology developed in the frame of the collaboration exceptionally relevant.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment